Transcriptional activation of RAR‐reporter constructs by tRA was found to be maximal between 0.1 and 10 μM (Allenby et al. 1993 ), and experiments with glial cultures showed strong effects with 0.01–1 μM (van Neerven, Regen, et al., 2010 ). To test the molecular regulation of phagocytosis we therefore tested 10 nM, 0.1 μM, and 0.5 μM of the pan‐RAR agonist all‐tRA (R2625; Sigma); 0.1 and 0.5 μM pan‐RXR agonist bexarotene (153559‐49‐0; LC Laboratories); 1 μM pan‐RXR antagonist UVI3003 (3303; Tocris); 1 μM RARβ agonist‐RARα/γ antagonist BMS189453 (SML1149; identical to BMS453; Sigma); 1 and 10 μM pan LXR agonist T0901317 (Cay71810‐10; Cayman); 9 and 18 μM PPARα agonist fenofibrate (Cay10005368‐1; Cayman); 50 nM and 0.1 μM PPARγ antagonist rosiglitazone (LKT‐R5773.100; LKT Laboratories); 0.2 and 0.5 μM PPARβ/δ agonist GW501516 (Cay10004272‐1; Cayman); 1 and 2 μM FXR agonist GW4064 (Cay10006611‐5; Cayman); 0.5 and 1 μM TGM2 inhibitor cystamine dihydrochloride (B22873.14; Alfa Aesar); 15, 25, 50, and 100 μM TGM2 inhibitor ERW1041E (5095220001; Merck); and 1, 5, and 25 μM blocker of scavenger receptor CD36 sulfo‐N‐succinimidyl oleate (SSO; SML2148; Merck).
Bms189453
Manufactured by Merck Group
BMS189453 is a laboratory equipment product manufactured by Merck Group. It is designed to perform a specific function within a laboratory setting. However, a detailed and unbiased description of the core function of this product cannot be provided without the risk of extrapolation or interpretation. Therefore, the description for this product is not available.
Automatically generated - may contain errors
Lab products found in correlation
Cystamine dihydrochloride, by Thermo Fisher Scientific (1 mentions)
Fenofibrate, by Cayman Chemical (1 mentions)
Gw4064, by Cayman Chemical (1 mentions)
Uvi3003, by Bio-Techne (1 mentions)
Bms453, by Merck Group (1 mentions)
Sml2148, by Merck Group (1 mentions)
Gw501516, by Cayman Chemical (1 mentions)
T0901317, by Cayman Chemical (1 mentions)
R2625, by Merck Group (1 mentions)
Bexarotene, by LC Laboratories (1 mentions)
Rosiglitazone, by LKT Laboratories (1 mentions)
2 protocols using bms189453
1
Molecular Regulation of Phagocytosis
2
Cardiac Differentiation of Human iPSCs
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Human iPS cells were maintained and differentiated to LPM with StemoleculeTM CHIR99021 for 48 h. BMS-189453 (1–2 µM, Sigma Aldrich, St. Louis, MO) was supplemented together with StemoleculeTM Wnt inhibitor IWP-4 (Stemgent, San Diego, CA) in RPMI-INS for 48 h starting day 3. Then, BMS-189453 treatment was continued after an additional 48 h after withdrawal of StemoleculeTM Wnt inhibitor IWP-4 in RPMI-INS until day 9. Culture medium was then switched to RPMI supplemented with insulin-containing B27 to further maintain the differentiated ventricular myocytes until use.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!